Abstract
MYB fusions are recurrently found in select cancers, including blastic plasmacytoid DC neoplasm (BPDCN), an acute leukemia with poor prognosis. They are markedly enriched in BPDCN compared with other blood cancers and, in some patients, are the only obvious somatic mutation detected. This suggests that they may alone be sufficient to drive DC transformation. MYB fusions are hypothesized to alter the normal transcription factor activity of MYB, but, mechanistically, how they promote leukemogenesis is poorly understood. Using CUT&RUN chromatin profiling, we found that, in BPDCN leukemogenesis, MYB switches from being a regulator of DC lineage genes to aberrantly regulating G2/M cell cycle control genes. MYB fusions found in patients with BPDCN increased the magnitude of DNA binding at these locations, and this was linked to BPDCN-associated gene expression changes. Furthermore, expression of MYB fusions in vivo impaired DC differentiation and induced transformation to generate a mouse model of myeloid-dendritic acute leukemia. Therapeutically, we present evidence that all-trans retinoic acid (ATRA) may cause loss of MYB protein and cell death in BPDCN.
Authors
Christopher A.G. Booth, Juliette M. Bouyssou, Katsuhiro Togami, Olivier Armand, Hembly G. Rivas, Kezhi Yan, Siobhan Rice, Shuyuan Cheng, Emily M. Lachtara, Jean-Pierre Bourquin, Alex Kentsis, Esther Rheinbay, James A. DeCaprio, Andrew A. Lane
Figure 5
MYB::PLEKHO1 can independently overcome G1/S arrest to induce leukemia.
